據報新冠口服藥莫諾拉韋在內地首發 今日可送達上海醫療機構
《澎湃新聞》報道,默沙東與Ridgeback生物技術公司合作研發的抗新冠病毒口服藥物莫諾拉韋(Molnupiravir)膠囊在中國市場首發。國藥控股(01099.HK)總裁劉勇表示,該藥將通過醫療機構進行配藥銷售。首發的藥物今日(13日)可以送達上海的醫療機構,今晚或明日(14日)可到達全國其他地方。
他表示,當前國藥控股正在與默沙東緊密協作,爭分奪秒推進藥物供應步伐。國藥控股針對春節期間供需和物流特點等已制定進口、倉儲及全國發運預案。預計春節前後可實現大量分批次到貨,並將綜合運用內地多口岸聯動、多倉發運等措施提高藥物可及性,惠及更多的新冠病毒感染患者。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.